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Insulin-like growth factor 1 (IGF-1) signaling promotes brain development and plasticity.
Altered IGF-1 expression has been associated to autism spectrum disorders (ASD). IGF-1
levels were found increased in the blood and decreased in the cerebrospinal fluid of ASD
children. Accordingly, IGF-1 treatment can rescue behavioral deficits in mouse models of
ASD, and IGF-1 trials have been proposed for ASD children. IGF-1 is mainly synthesized
in the liver, and its synthesis is dependent on growth hormone (GH) produced in the
pituitary gland. GH also modulates cognitive functions, and altered levels of GH have
been detected in ASD patients. Here, we analyzed the expression of GH, IGF-1, their
receptors, and regulatory hormones in the neuroendocrine system of adult male mice
lacking the homeobox transcription factor Engrailed-2 (En2−/− mice). En2−/− mice dis-
play ASD-like behaviors (social interactions, defective spatial learning, increased seizure
susceptibility) accompanied by relevant neuropathological changes (loss of cerebellar and
forebrain inhibitory neurons). Recent studies showed that En2 modulates IGF-1 activity dur-
ing postnatal cerebellar development. We found that GH mRNA expression was markedly
deregulated throughout the neuroendocrine axis in En2−/− mice, as compared to wild-
type controls. In mutant mice, GH mRNA levels were significantly increased in the pituitary
gland, blood, and liver, whereas decreased levels were detected in the hippocampus.These
changes were paralleled by decreased levels of GH protein in the hippocampus but not
other tissues of En2−/− mice. IGF-1 mRNA was significantly up-regulated in the liver and
down-regulated in the En2−/− hippocampus, but no differences were detected in the levels
of IGF-1 protein between the two genotypes. Our data strengthen the notion that altered
GH levels in the hippocampus may be involved in learning disabilities associated to ASD.
Keywords: autism spectrum disorders, hippocampus, pituitary gland, liver, growth hormone, insulin-like growth
factor, neuroendocrine axis, mouse model
INTRODUCTION
Insulin-like growth factor 1 (IGF-1) is a hormone primarily pro-
duced by the liver, which exerts an endocrine action on multiple
target tissues. It is also locally produced in tissues, including brain,
where it acts in a paracrine/autocrine fashion. Several studies
demonstrate that IGF-1 profoundly modulates brain function,
both during development and adult life. During development,
IGF-1 promotes neuronal survival [reviewed in Ref. (1)] and mat-
uration of cortical and retinal function (2–4), whereas in adult
life, it exerts multiple actions ranging from the control of synap-
tic plasticity to neuroprotection [reviewed in Ref. (1, 5)]. During
adulthood, IGF-1 is crucial for both basal and exercise-induced
hippocampal neurogenesis (6, 7) and markedly regulates learning
and cognition (8).
A link between IGF-1 pathway and autism spectrum disor-
ders (ASD) has been proposed. IGF-1 levels have been found
increased in the blood (9) and decreased in the cerebrospinal fluid
(10, 11) of ASD children, as compared to healthy individuals. In
addition, deregulation of IGF-1 signaling pathway, which involves
downstream effectors such as PI3 kinase (PI3K), protein kinase B
(AKT), and mammalian target of rapamycin (mTOR), has been
shown in syndromic forms of ASD [reviewed in Ref. (12)]. This led
to propose that IGF-1 treatment might be beneficial for ASD, and
clinical trials have been approved1. Indeed, IGF-1 administration
is able to rescue ASD-related molecular changes in neurons derived
from ASD patients (13) as well as ASD-like behavioral deficits in
mouse models (14, 15). Altered levels of other hormones of the
IGF-1 pathway have been associated to ASD (9). IGF-1 synthe-
sis in the liver depends on levels of circulating growth hormone
(GH) produced in the pituitary gland. GH also modulates cogni-
tive functions (16), and altered GH levels have been detected in
ASD patients (17).
Genome-wide association studies identified the transcription
factor Engrailed-2 (En2) as a candidate gene for ASD (18), and
two recent studies confirmed that En2 expression is altered in the
1http://clinicaltrials.gov
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cerebellum of ASD patients (19, 20). Mice lacking the homeobox
domain of En2 [En2hd/hd mice; (21); here referred to as En2−/−]
are considered a suitable animal model to study the neurodevelop-
mental basis of ASD. En2−/− mice display neuropathological and
behavioral changes relevant to ASD. Reduced social interactions,
defective spatial learning (22–24), and increased seizure suscepti-
bility (25) accompanied by neuropathological changes relevant to
ASD [loss of cerebellar and forebrain inhibitory neurons; (26, 27)]
were indeed described in En2−/− mice. In addition, we recently
showed that several genes related to ASD are markedly dereg-
ulated in the cerebellum and hippocampus of En2−/− mice (28),
thus indicating that En2 mutants are a reliable model to investigate
gene expression changes relevant to ASD.
A recent study established an important link between En2
and the modulation of IGF-1 pathway (29). During postnatal
development, En2 controls proliferation and differentiation of
cerebellar granule neuron precursors (GNPs). Notably, in post-
natal En2−/− cerebellum, the activity of downstream effectors of
IGF-1 is increased, and IGF-1 has a stronger mitogenic effect on
GNPs, as compared to WT (29). These results indicate that En2
negatively regulates IGF-1 signaling during postnatal cerebellar
development.
Here, we investigated the relationship between En2 and
GH/IGF-1 pathway in the neuroendocrine system. We analyzed
the expression of GH, IGF-1, their receptors, and regulatory hor-
mones in the brain–pituitary–liver axis of adult wild-type (WT)
and En2−/− mice. We show that GH levels are lowered in the hip-
pocampus of En2−/− mice, suggesting that this alteration might
contribute to learning disabilities in this ASD mouse model.
MATERIALS AND METHODS
ANIMALS
Experiments were conducted in conformity with the European
Community Directive 2010/63/EU and were approved by the Ital-
ian Ministry of Health. Animals were housed in a 12-h light/dark
cycle with food and water available ad libitum, and all efforts were
made to minimize animal suffering during the experiments. The
generation of En2 mutants were originally generated on a mixed
129Sv×C57BL/6 genetic background (21) and then backcrossed
at least five times into a C57BL/6 background (27). En2+/+ (WT)
and En2−/− mice used in this study were obtained by heterozy-
gous mating (En2±× En2±) and genotyped by PCR as previously
described (27). A total of 34 adult (3–5 months old) male mice
were used: 6 mice per genotype for quantitative RT-PCR, 5 mice
per genotype for enzyme-linked immuno-sorbent assay (ELISA)
tests, 3 mice per genotype for immunohistochemistry, and 3 mice
per genotype for in situ hybridization.
QUANTITATIVE RT-PCR
Tissues from WT and En2−/− mice (n= 6 per genotype) were
dissected and frozen in dry ice. Blood samples were centrifuged
in an Eppendorf benchtop centrifuge for 15 min at 3,000 rpm to
separate serum from cell fraction, and then frozen in dry ice. All
samples were stored at−80°C until use. Total RNAs were extracted
by Trizol reagent (Invitrogen), treated with DNAse, purified by the
RNAeasy Kit (Qiagen), and pooled. cDNAs were synthesized from
pooled RNAs (3µg) by SuperScript VILO cDNA Synthesis Kit
(Invitrogen). Quantitative reverse-transcription PCR (RT-PCR)
was performed in a C1000 thermal cycler (BioRad) with real-
time detection of fluorescence, using the KAPA SYBR FAST master
mix reagent (Resnova). Mouse mitochondrial ribosomal protein
L41 (Mrpl41) was used as a standard for quantification. Primers
(Sigma Genosys, UK) sequences are reported in Table 1. Ratios
of comparative concentrations of each mRNA with respect to L41
mRNA were then calculated and plotted as the average of three
to four independent reactions with technical replicates obtained
from each RNA pool. Expression analyses were performed using
the CFX3 Manager (BioRad) software.
BIOINFORMATIC ANALYSIS
Analysis of En2 binding sites on GH, GHR, mGRF, SST, IGF-1, and
IGF-1R gene promoters was performed using the Matinspector
web-based search algorithm available from Genomatix Software2.
The algorithm calculated the similarity between the core motif
and overall sequence of the En2 consensus binding site (matrix ID:
V$EN2.01) and the gene promoter sequences of interest. The En2
matrix was determined based on the Genomatix Matrix Library
Version 9.1.
IMMUNOHISTOCHEMISTRY
Brains from adult WT and En2−/− mice (n= 3 per geno-
type) were used for immunohistochemical characterization of
2http://www.Genomatix.de
Table 1 | Primers used for quantitative RT-PCR experiments.
Gene GenBank no. Forward primer (5’–3’) Reverse primer (5’–3’)
En2 NM_010134.3 ACTGCACGCGCTATTCTG ACCTGTTGGTCTGAAACTCAG
GH NM_008117.3 GCAATGGCTACAGACTCT AAACAGACTGGACAAGGG
GHR NM_001286370.1 CGTTCCCCTGAACTGGAGAC CAGCTTGTCGTTGGCTTTCC
IGF-1 class 1 NM_001111275.1 AGCGATGGGGAAAATCAGCA CAGAGCGCCAGGTAGAAGAG
IGF-1 class 2 NM_001111276.1 CTGATGTCTGGTCCTTCGGG CACCCTCCATGACGAAACGA
IGF-1R NM_010513.2 CTGATGTCTGGTCCTTCGGG CACCCTCCATGACGAAACGA
mGRF NM_010285.2 AGGATCCAGGAACAAAGGGC GCAAGATGCTCTCCAGGGTC
SST NM_009215 AGGACGAGATGAGGCTGG CAGGAGTTAAGGAAGAGATATGGG
Abbreviations are as in the text.
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hypothalamic SST. Brains were fixed by transcardial perfusion with
4% paraformaldehyde followed by 1 h post-fixation, and coronal
sections (40µm thickness) were cut by a vibratome (Leica). Serial
sections at level of the hypothalamus were incubated overnight
with and anti-SST rabbit polyclonal (Peninsula-Bachem; 1:2000
dilution). Signals were revealed using appropriate secondary anti-
bodies and fluorophores as described (27). Hypothalamic nuclei
were identified according to the Allen Brain Atlas3. Images were
acquired at 10× objective magnification using a Zeiss AxioImager
M2 microscope.
IN SITU HYBRIDIZATION
Brains from WT and En2−/− mice (n= 3 per genotype) were
rapidly removed and frozen on dry ice. Coronal cryostat
sections (20µm thick) were fixed in 4% paraformaldehyde. Non-
radioactive in situ hybridization was performed as previously
described (27) using digoxigenin-labeled riboprobes specific for
GH [GenBank ID: X02891; (30)], mGRF (31), and IGF-1 (Gen-
Bank ID: NM_010512). The IGF-1 cDNA was cloned by PCR from
hippocampal cDNA and recognizes both class 1 and class 2 IGF-1
mRNAs. Signal was detected by alkaline phosphatase-conjugated
anti-digoxigenin antibody followed by alkaline phosphatase stain-
ing. The specificity of the results was confirmed by the use of sense
riboprobes (not shown).
ENZYME-LINKED IMMUNO-SORBENT ASSAY
Blood samples (n= 5 per genotype) were collected at the time of
animal sacrifice, kept in ice for 30 min, and then centrifuged in an
Eppendorf benchtop centrifuge for 15 min at 3,000 rpm to sep-
arate serum. Dissected liver and hippocampal tissues (n= 5 per
genotype) were homogenized in lysis buffer (50 mM Tris–HCl pH
7.5, 1% NP-40, 1% Triton-100, 1 mM PMSF, 10% glycerol, and
protease inhibitor cocktail; Sigma-Aldrich). Homogenates were
incubated in ice for 30 min, centrifuged at 12,000 rpm for 5 min
at 4°C, and supernatants were recovered and stored at −80°C.
Protein concentration in serum, liver, and hippocampal samples
was determined by BCA method (Pierce). Samples were processed
for GH (EZRMGH-45K, Millipore) and IGF-1 (ELM-IGFI; Ray-
Biotech) ELISA according to manufacturers’ protocol. All samples
were analyzed in duplicate.
STATISTICAL ANALYSIS
Statistical analysis was performed with SigmaPlot 11.0 and Prism 6
(GraphPad) softwares. Values were expressed as mean± SEM and
quantitative gene expression differences between WT and En2−/−
mice were assessed by Student’s t -test, with the level of statistical
significance set at p< 0.05.
RESULTS
EXPRESSION OF En2 AND IGF-1 SIGNALING GENES IN THE MOUSE
BRAIN–PITUITARY–LIVER AXIS
By using quantitative RT-PCR, we first investigated mRNA expres-
sion of En2, GH, GH receptor (GHR), mGRF, SST, IGF-1, and
IGF-1 receptor (IGF-1R) in the neuroendocrine axis of WT adult
3http://www.brain-map.org/
male mice from our colony. mRNA expression was studied in
the hypothalamus, pituitary gland, and liver (the crucial tissues
involved in GH and IGF-1 synthesis), as well as hippocampus
and blood cell fraction. In agreement with previous findings,
we confirmed that En2 mRNA is expressed in the hypothalamus
and hippocampus (23, 25, 27). En2 mRNA was also expressed at
detectable levels in blood, pituitary gland, and liver (Figure 1A). As
expected, GH mRNA was mainly detected in the pituitary gland,
while much lower levels were present in the hippocampus, hypo-
thalamus, liver, and blood (Figure 1B). Consistent with the notion
that liver is the main target of GH action, we found GHR mRNA
predominantly expressed in the liver, and at lower levels in the
other tissues analyzed (Figure 1C). mRNA expression of mGRF
and SST, the two hypothalamic hormones controlling GH syn-
thesis, was mainly detected in the hypothalamus (Figures 1D,E).
High levels of SST mRNA were also present in the hippocampus,
as previously described (27). Two major different transcripts have
been described for IGF-1 [class 1 and class 2; (32, 33)]. Both IGF-
1 class 1 and class 2 mRNAs were predominantly expressed in
the liver (Figures 1F,G), as expected (32). Finally, IGF-1R mRNA
was mainly expressed in the pituitary gland (the target for IGF-
1 negative feedback for GH production) (Figure 1H), but also
throughout the neuroendocrine axis, consistent with the wide-
spread action of IGF-1 on multiple tissues. These results clearly
indicate that our RT-PCR protocol can detect the expression of
genes belonging to the GH/IGF-1 pathway in the appropriate
tissues throughout the brain–pituitary–liver axis.
ALTERED GH mRNA EXPRESSION IN THE BRAIN–PITUITARY–LIVER
AXIS OF En2−/− MICE
Before investigating GH, GHR, mGRF, SST, IGF-1, and IGF-1R
mRNA expression in the neuroendocrine axis of En2−/− mice,
we first verified whether En2 might directly regulate their tran-
scription. Indeed, bioinformatic analysis revealed thatEn2 binding
sites are present in the promoters of all these genes (Table 2).
We next studied GH and GHR mRNA expression in the neu-
roendocrine axis of WT and En2−/− adult mice. We found that
GH mRNA expression was markedly deregulated throughout
the neuroendocrine axis in En2−/− mice. A statistically signifi-
cant increase of GH mRNA levels was detected in the pituitary
gland (+72%, p< 0.001), liver (+376%, p< 0.001), and blood
(+87%, p< 0.05) of En2−/− mice, as compared to WT litter-
mates (Figure 2A). GH mRNA levels were instead significantly
lower in the En2−/− hypothalamus (−97%, p< 0.001) and hip-
pocampus (−98%, p< 0.001), as compared to WT (Figure 2A).
In situ hybridization confirmed GH mRNA decrease in theEn2−/−
hippocampus, mainly in the CA3 subfield (Figure 2C). No sig-
nificant differences in GHR mRNA levels were detected between
genotypes in the analyzed tissues, with the exception of blood,
where a marked increase was detected in mutant mice compared
to controls (+312%, p< 0.05) (Figure 2B).
ALTERED EXPRESSION OF mGRF AND SST IN THE HYPOTHALAMUS OF
En2−/− MICE
We then investigated the expression of mGRF (also known
as growth hormone releasing hormone, GHRH) and SST, the
two hypothalamic hormones regulating GH synthesis, in the
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FIGURE 1 | mRNA expression of En2 and genes involved in the GH/IGF-1
pathway in the neuroendocrine axis of WT mice. En2 (A), GH (B), GHR
(C), mGRF (D), SST (E), IGF-1 (F,G), and IGF-1R (H) mRNA expression levels
in the hippocampus, hypothalamus, pituitary gland, liver, and blood, obtained
by quantitative RT-PCR. For each mRNA, relative expression levels
(normalized to L41) are reported on a log scale. Two different transcripts (class
1 and class 2) were analyzed for IGF-1. Values are plotted as mean±SEM of
three independent experiments. Abbreviations: hi, hippocampus; hy,
hypothalamus; pit, pituitary gland; liv, liver; bld, blood (cell fraction). Other
abbreviations are as in the text.
Table 2 | Presence of En2 binding sites onto GH, GHR, mGRF, SST, IGF-1, and IGF-1R gene promoters.
Gene Accession no. Start End Strand Core Matrix Sequence
GH GXP_219787 534 552 + 0.752 0.73 agccatgAATAaatgtata
GHR GXP_889069 584 602 – 1 0.863 ccccataAATTaataatcc
IGF-1 GXP_4345839 966 984 – 1 0.858 ttttatgAATTaagccctc
IGF-1R GXP_183481 512 530 – 1 0.854 aacattgAATTagttcttg
mGRF GXP_4357410 266 284 – 1 0.797 ggaaacaAATTgaacaaat
SST GXP_82140 62 80 – 1 0.774 cagaatgAATTtgcaatta
The promoter regions of the six genes belonging to the GH/IGF-1 pathway were analyzed for the presence of En2 binding site using the Matinspector program. Core
similarity (Core) indicates the match against the nucleotides representing the core motif of the En2 binding site (AATT), where 1 is 100% identity. Matrix similarity
(Matrix) is the overall similarity to the En2 binding motif, where 1 is 100% identity. For each sequence, the start/end position respect to ATG is indicated, together
with the strand on which they are present. For each promoter, several regions containing the En2 binding site were found; the table reports only those with highest
values for core and matrix similarity. Genomatix Promoter database (GXP) accession numbers are given for each gene. Abbreviations are as in the text.
brain–pituitary–liver axis of WT and En2−/− adult mice. As com-
pared to WT controls, a marked increase of mGRF mRNA (+53%,
p< 0.05; Figure 3A) and a significant decrease of SST mRNA
(−13%, p< 0.01; Figure 3B) was found in the En2−/− hypothala-
mus. Significantly higher mRNA levels for the two hormones were
also found in blood (mGRF:+125%, p< 0.05) and liver (mGRF:
+129%, p< 0.01; SST: +147%, p< 0.001) from En2−/− mice
(Figures 3A,B). According to our previous study (27), lower levels
of SST mRNA were found in the En2−/− hippocampus, as com-
pared to WT (−10%, p< 0.05; Figure 3B). In situ hybridization
and immunohistochemistry experiments, respectively, confirmed
the increased expression of mGRF mRNA and decreased levels
of SST protein in the dorsomedial/ventromedial paraventricu-
lar nuclei of the En2−/− hypothalamus, as compared to WT
(Figure 3C).
ALTERED IGF-1 mRNA EXPRESSION IN THE BRAIN–PITUITARY–LIVER
AXIS OF En2−/− MICE
We next analyzed mRNA expression of IGF-1 and its receptor
in the brain–pituitary–liver axis of WT and En2−/− adult mice.
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FIGURE 2 | Expression of GH and GH receptor mRNAs in the
neuroendocrine axis of WT and En2−/− mice. (A) GH mRNA quantitative
RT-PCR. (B) GHR quantitative RT-PCR. Values are plotted as each gene/L41
comparative quantitation ratios normalized on the expression of WT
(mean±SEM of three replicates from pools of six animals per genotype;
*p<0.05, ***p<0.001; Student’s t -test, En2−/− vs. WT).
(C) Representative pictures of GH mRNA in situ hybridization on the dorsal
hippocampus from WT and En2−/− mice. Insets show the CA3 subfield.
Scale bar: 200µm (whole hippocampi) and 125µm (insets). Abbreviations
are as in Figure 1.
IGF-1 mRNA exists in two major forms (class 1 and class 2),
class 2 mRNA transcription being directly regulated by GH (33,
34). We found that levels of IGF-1 class 1 mRNA were signif-
icantly reduced in the hippocampus but not other tissues of
En2−/−mice, as compared to WT (−18%,p< 0.05 for all compar-
isons) (Figure 4A). In keeping with GH mRNA expression data
(Figure 2), IGF-1 class 2 mRNA was significantly up-regulated in
the liver (+43%, p< 0.001) and down-regulated in the hypothal-
amus (−19%, p< 0.001) of En2−/− mice, as compared to WT
littermates; increased levels of IGF-1 class 2 mRNA were also
detected in En2−/− pituitary gland (+16%, p< 0.01) and blood
(+312%,p< 0.001) (Figure 4B). In situ hybridization with a ribo-
probe specific for both class 1 and class 2 IGF-1 mRNAs confirmed
that IGF-1 mRNA levels are decreased in theEn2−/− hippocampus
(Figure 4D). Finally, IGF-1R mRNA levels did not differ between
genotypes in hypothalamus, hippocampus, and pituitary gland,
while a significant increase was found in blood (+84%, p< 0.01)
and liver (+52%, p< 0.05) from En2−/− mice compared to WT
controls (Figure 4C). Table 3 summarizes mRNA expression data
for all the analyzed genes in the brain–pituitary–liver axis of WT
and En2−/− adult mice.
REDUCED LEVELS OF GH PROTEIN IN THE En2−/− HIPPOCAMPUS
The altered levels of GH and IGF-1 mRNA expression detected in
the En2−/− neuroendocrine axis prompted us to investigate the
levels of these hormones in the hippocampus, serum, and liver
of both genotypes. ELISA assays revealed a significant reduction
(−54%, p< 0.05) of GH protein levels in the hippocampus of
FIGURE 3 | Expression of mGRF and SST mRNAs in the
neuroendocrine axis of WT and En2−/− mice. (A,B) mRNA expression
levels of mGRF (A) and SST (B), obtained by quantitative RT-PCR. Values
are plotted as each gene/L41 comparative quantitation ratios normalized on
the expression of WT (mean±SEM of three replicates from pools of six
animals per genotype; *p< 0.05, **p<0.01; Student’s t -test, En2−/− vs.
WT). (C) mGRF in situ hybridization and SST immunohistochemistry.
Representative pictures show mGRF mRNA and SST protein staining in the
dorsomedial and ventromedial paraventricular nuclei of the hypothalamus.
Scale bar: 200µm. Abbreviations are as in Figure 1.
En2−/− mice, as compared to WT littermates, while no difference
was detected in serum samples (Figure 5A). Hippocampal, liver,
and serum IGF-1 protein levels did not significantly differ between
the two genotypes (Figure 5B).
DISCUSSION
BRIEF SUMMARY OF RESULTS
In this study, we analyzed the expression of GH, IGF-1, their recep-
tors, and regulatory hormones in the brain–pituitary–liver axis
of adult En2−/− mice, a mouse model for ASD. We found that
in mutant mice, GH and IGF-1 mRNA levels were significantly
www.frontiersin.org September 2014 | Volume 2 | Article 92 | 5
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higher in the pituitary gland and liver, respectively,but this increase
was not paralleled by higher levels of circulating hormones. In
En2 mutants, GH and IGF-1 mRNA levels were instead signif-
icantly down-regulated in the hippocampus, and this reduction
was accompanied by a significant decrease of GH but not IGF-1
protein levels.
En2 INTERACTS WITH IGF-1 SIGNALING IN THE MOUSE
NEUROENDOCRINE AXIS
Our results, schematically summarized in Figure 6, indicate
that regulatory mechanisms controlling GH and IGF-1 mRNA
FIGURE 4 | Expression of IGF-1 and IGF-1R mRNAs in the
neuroendocrine axis of WT and En2−/− mice. (A,B) Quantitative RT-PCR
for IGF-1 class 1 (A) and class 2 (B) transcripts. (C) IGF-1R quantitative
RT-PCR. Values are plotted as each gene/L41 comparative quantitation ratios
normalized on the expression of WT (mean±SEM of three replicates from
pools of six animals per genotype; *p<0.05, **p<0.01; ***p<0.001;
Student’s t -test, En2−/− vs. WT). (D) Representative pictures of in situ
hybridization for IGF-1 mRNA (both transcripts) on the dorsal hippocampus
from WT and En2−/− mice. Insets show the CA3 subfield. Scale bar: 200µm
(whole hippocampi) and 125µm (insets). Abbreviations are as in Figure 1.
expression in the neuroendocrine system are altered in En2−/−
mice. The presence of En2 mRNA in the hypothalamus–pituitary–
liver axis (Figure 1) and that of an En2 binding site in the pro-
moters of GH, IGF-1, and other genes of the pathway (Table 2)
suggest that En2 might directly contribute to their transcrip-
tional control. Indeed, recent studies revealed an unprecedented
interaction between En2 and IGF-1 signaling. In the absence of
En2, IGF-1 has a stronger mitogenic effect on cerebellar GNPs,
due the increased activity of downstream effectors of IGF-1 sig-
naling, such as S6 kinase (29). Thus, En2 appears to negatively
regulate IGF-1 signaling during postnatal cerebellar development.
Our results strengthen this link between En2 and IGF-1 signal-
ing, and suggest that a direct transcriptional control of En2 onto
genes belonging to the IGF-1 pathway takes place also in the
brain–pituitary–liver axis.
FIGURE 5 | Levels of GH and IGF-1 hormones inWT and En2−/− mice.
(A,B) ELISA quantification of GH (A) and IGF-1 (B) levels in serum and
hippocampal (hippo) and liver protein extracts, as indicated. Values are
plotted as mean±SEM (five animals per genotype, in duplicate; *p<0.05,
Student’s t -test, En2−/− vs. WT). Genotypes are as indicated.
Table 3 | Summary of the expression of En2, GH, GHR, mGRF, SST, IGF-1, and IGF-1R mRNAs in the neuroendocrine axis of En2−/− mice, as
compared toWT.
Gene Hippocampus Hypothalamus Pituitary Liver Blood
GH −98%*** −97%*** +72%*** +376%*** +87%*
GHR No difference No difference No difference No difference +312%*
mGRF No difference +53%* No difference +129%** +125%*
SST −10%* −13%** No difference +147%** No difference
IGF-1 Class 1 −18%* No difference No difference No difference No difference
IGF-1 Class 2 No difference −19%*** +16%** +43%*** +312%***
IGF-1R No difference No difference No difference +52%* +84%**
Summary of quantitative RT-PCR data. Data are presented as the mean percentage of the decrease/increase of each mRNA in En2−/− mice, as compared to WT
littermates.
Statistical significance: *p< 0.05, **p<0.01, ***p<0.001 (En2−/− vs. WT). Abbreviations are as in the text.
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FIGURE 6 | Schematic summary of SST, mGRF, GH, and IGF-1
expression in the En2−/− neuroendocrine axis. Red and blue arrows,
respectively, indicate up- and down-regulations observed in En2−/− mice as
compared to WT controls. Double-arrowed gray lines indicate comparable
levels between WT and En2−/− mice. Increased levels of GH and IGF-1
mRNA, respectively observed in En2−/− pituitary and liver, are not paralleled
by higher levels of circulating hormones, suggesting that a complex
post-translational control of GH and IGF-1 synthesis takes place in mutant
mice. GH mRNA and protein levels are instead significantly down-regulated
in En2−/− hippocampus. Arrowed red lines connecting different organs
indicate the action of circulating hormones onto their target tissues. The
mouse brain sagittal section is a Nissl stain taken from the Allen Mouse
Brain Atlas (see text footnote 2). Abbreviations are as in the text.
DIFFERENTIAL EXPRESSION OF GH AND IGF-1 mRNAs IN THE BRAIN
AND PERIPHERAL TISSUES OF En2−/− MICE
IGF-1 mRNA exists in two main isoforms, derived from alterna-
tive splicing of the two first exons contained in the 5′ untranslated
region (5′ UTR) of the mRNA precursor. Class 1 transcripts
contain exon 1, whereas class 2 transcripts contain exon 2 (33).
Inclusion of exon 1 or exon 2 is mutually exclusive, resulting in
different 5′ UTRs of the IGF-1 mRNA containing different leader
sequences of the pre-pro-IGF-I peptide. In addition, transcrip-
tion of class 1 and class 2 mRNAs is differently controlled; class 2
mRNA being directly regulated by GH. It is, however, important
to note that both class 1 and class 2 transcripts code for the same
IGF-1 mature peptide (33).
In En2 mutants, we described a differential expression of IGF-
1 mRNAs in different tissues of the brain–pituitary–liver axis.
A significant increase of IGF-1 class 2 mRNA was detected in
liver and blood, whereas IGF-1 class 1 mRNA was significantly
decreased in the En2−/− hippocampus (Figure 4). The negative
regulation exerted by En2 onto IGF-1 signaling in the cerebellum
(29), therefore, appears to occur also at a transcriptional level in
the hippocampus.
Interestingly,En2−/−mice showed increased hypothalamic lev-
els of mGRF and decreased levels of somatostatin (SST), the
two hormones controlling GH synthesis. Previous studies from
our laboratory already showed that loss of En2 results in lower
levels of SST mRNA and protein in the hippocampus and cere-
bral cortex. Here, we extended this observation, demonstrating
that lower levels of SST are also present in the En2−/− hypo-
thalamus; hypothalamic levels of mGRF mRNA were instead
increased in mutant mice (Figure 3). Deregulation of hypothala-
mic hormones controlling GH synthesis might result in increased
levels of circulating GH and IGF-1 in mutant mice. However,
we showed that serum levels of both hormones, as well as IGF-
1 levels in liver did not differ between WT and En2−/− mice
(Figure 5). Indeed, behavioral studies did not reveal gross weight
and growth abnormalities in En2 mutants (23), suggesting that
differences in GH and IGF-1 mRNA levels might be blunted at
the protein level, via multiple post-transcriptional control mecha-
nisms. Indeed, a tight dependence of IGF-1 translation via several
miRNA binding site in the 3′ UTR of the transcripts has been
described (33, 35).
FUNCTIONAL CONSEQUENCES OF REDUCED GH LEVELS IN THE En2−/−
HIPPOCAMPUS
The decreased expression of GH mRNA and protein observed in
the En2−/− hippocampus might contribute to learning deficits
observed in En2 mutants. Indeed, En2−/− mice show impaired
learning in hippocampal-dependent tasks, such as the Morris
water maze and contextual fear conditioning (22, 23). Pro-
found effects on cognitive function have been demonstrated
for GH. GH-deficient spontaneous dwarf rats display marked
deficits in hippocampus-dependent spatial learning and mem-
ory, accompanied by an imbalance in hippocampal glutamater-
gic/GABAergic synapses and neurogenesis (36). Chronic stress,
which is known to affect hippocampal function, also reduces hip-
pocampal GH levels (37). Restoration of normal GH levels in
the hippocampus (obtained via viral-mediated gene transfer) is
able to reverse stress-dependent behavioral impairment, as tested
by hippocampus-dependent tasks (contextual fear conditioning)
(37). Taken together, these results indicate that reduced levels of
hippocampal GH detected in En2−/− mice might contribute to
hippocampal dysfunction observed in these mutants.
CONCLUSION
To our knowledge, this is the first demonstration that brain GH
levels are reduced in a mouse model of ASD. Considering the
important role of GH on cognitive functions, our data strengthen
the notion that reduced expression of GH in the hippocampus
may be implicated in learning disabilities associated to ASD.
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